Non-melanoma skin cancer (NMSC) is a common type of skin cancer that includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). It is typically caused by exposure to ultraviolet (UV) radiation from the sun or tanning beds. NMSC is highly treatable when detected early, but it can be disfiguring and even life-threatening if left untreated. The global market for NMSC treatments is growing rapidly, driven by the increasing incidence of the disease and the development of new and innovative therapies.
Radiation therapy dominates non-melanoma skin cancer treatment market
Radiation therapy has a market share approaching 90% in the non-melanoma skin cancer treatment market in 2017 itself and is unlikely to cede this commanding position anytime soon. Radiation therapy has a value of approx. US$ 4.8 Bn by end 2025 making it considerably larger than both chemotherapy and photodynamic therapy. Within radiation therapy, external beam radiation therapy is currently the largest in terms of market value.
Treatment Types:
There are several types of treatments available for NMSC, including surgery, radiation therapy, topical chemotherapy, and immunotherapy. Surgery is the most common treatment for NMSC, and it is highly effective in removing tumors. Radiation therapy is typically used for tumors that cannot be removed surgically, while topical chemotherapy is used for superficial tumors. Immunotherapy is a newer type of treatment that works by stimulating the body’s immune system to attack cancer cells.
Geographical Analysis:
The market for NMSC treatments is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is the largest market for NMSC treatments, followed by Europe and Asia Pacific. The high incidence of NMSC in the United States and Canada, coupled with the availability of advanced treatments and government-funded healthcare programs, is driving the market in North America. In Europe, the market is driven by the growing aging population and the increasing adoption of innovative therapies. The Asia Pacific market is expected to grow at the highest CAGR during the forecast period, owing to the large population and the increasing incidence of NMSC in countries such as China and India.
Key Players:
The major players operating in the NMSC market include Roche, Merck & Co., Inc., Novartis AG, Bristol-Myers Squibb, Sun Pharmaceutical Industries Ltd., Elekta AB, Varian Medical Systems, Inc., Valeant Pharmaceuticals International, Inc., and Mylan N.V. These companies are focusing on research and development activities to develop new and innovative therapies, as well as expanding their geographical presence through strategic partnerships and collaborations.
Get Free Sample Copy- https://www.persistencemarketresearch.com/samples/3648
Conclusion:
The global market for NMSC treatments is growing rapidly, driven by the increasing incidence of the disease and the development of new and innovative therapies. Surgery is the most common treatment for NMSC, and North America is the largest market for NMSC treatments. Key players in the market are focused on research and development activities to develop new and innovative therapies, as well as expanding their geographical presence through strategic partnerships and collaborations. With the growing aging population and increasing incidence of NMSC, the market is expected to continue to grow in the coming years.